1-20 of 32
Authors: Timothy Gershon
Journal Article
CTNI-20. ADDRESSING SKIN ADVERSE EVENTS (AES) DURING MIRDAMETINIB TREATMENT IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS (NF1-PN): GUIDANCE FROM A MULTIDISCIPLINARY GROUP OF EXPERTS ON THE MANAGEMENT OF MEK INHIBITOR-ASSOCIATED SKIN AES Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii100, https://doi.org/10.1093/neuonc/noae165.0387
Published: 11 November 2024
Journal Article
QOL-08. HEALTH-RELATED QUALITY-OF-LIFE (HRQOL) IN ADULTS AND CHILDREN WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN) TREATED WITH MIRDAMETINIB: PIVOTAL, PHASE 2B RENEU TRIAL Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii263, https://doi.org/10.1093/neuonc/noae165.1043
Published: 11 November 2024
Journal Article
CTNI-21. PIVOTAL, PHASE 2B RENEU TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN): A SPOTLIGHT ON PATIENTS ACHIEVING DEEP RESPONSE Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii100, https://doi.org/10.1093/neuonc/noae165.0388
Published: 11 November 2024
Journal Article
IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY Open Access
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i52, https://doi.org/10.1093/neuonc/noad073.201
Published: 12 June 2023
Journal Article
STEM-26. ASTROCYTIC SOX2+ CELLS RELAY IN NON-CANONICAL GLI SIGNALING TO FACILITATE MEDULLOBLASTOMA RELAPSE Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii36–vii37, https://doi.org/10.1093/neuonc/noac209.143
Published: 14 November 2022
Journal Article
TMIC-79. MYELOID-DIRECTED TREATMENT USING THE TLR7/8 AGONIST RESIQUIMOD IMPROVES THE SURVIVAL OF MICE WITH MEDULLOBLASTOMA AND ENHANCES EFFICACY OF RADIOTHERAPY Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii289, https://doi.org/10.1093/neuonc/noac209.1122
Published: 14 November 2022
Journal Article
TMET-01. DISRUPTION OF THE SERINE-PRODUCING PATHWAYS SLOWS PROGRESSION OF THE SONIC HEDGEHOG-DRIVEN MEDULLOBLASTOMA Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii261, https://doi.org/10.1093/neuonc/noac209.1006
Published: 14 November 2022
Journal Article
MEDB-56. POx NPs mediated delivery of (TLR7/8) agonist resiquimod improves treatment outcomes in SHH medulloblastoma by targeting tumor associated macrophages Open Access
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Page i119, https://doi.org/10.1093/neuonc/noac079.430
Published: 03 June 2022
Journal Article
IMMU-20. Effective CAR-T cell medulloblastoma therapy in an immunocompetent mouse model Open Access
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Page i86, https://doi.org/10.1093/neuonc/noac079.313
Published: 03 June 2022
Journal Article
IMMU-48. IMMUNOMODULATION WITH RESIQUIMOD REPOLARIZES THE IMMUNE MICROENVIRONMENT TO INHIBIT MEDULLOBLASTOMA PROGRESSION Free
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi103, https://doi.org/10.1093/neuonc/noab196.407
Published: 12 November 2021
Journal Article
CBIO-23. ANTIAPOPTOTIC Bcl-xL RESTRICTS APOPTOSIS IN SHH MEDULLOBLASTOMA AND PROMOTES PROGRESSION Free
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi31–vi32, https://doi.org/10.1093/neuonc/noab196.122
Published: 12 November 2021
Journal Article
EMBR-15. PRC2 COMPLEX ENFORCES NEURONAL LINEAGE AND SUPPRESSES TUMOR GROWTH IN SHH MEDULLOBLASTOMA Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Pages i8–i9, https://doi.org/10.1093/neuonc/noab090.033
Published: 01 June 2021
Journal Article
IMMU-05. IMMUNOTHERAPY WITH RESIQUIMOD REPOLARIZES TUMOR-ASSOCIATED MYELOID CELLS AND IMPROVES EVENT-FREE SURVIVAL IN A TRANSGENIC MOUSE MODEL OF SONIC-HEDGEHOG (SHH) MEDULLOBLASTOMA Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Pages i27–i28, https://doi.org/10.1093/neuonc/noab090.113
Published: 01 June 2021
Journal Article
EPCT-19. DRUG RESISTANCE IN MEDULLOBLASTOMA ADDRESSED WITH OLIG2 INHIBITOR, CT-179 Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Page i51, https://doi.org/10.1093/neuonc/noab090.205
Published: 01 June 2021
Journal Article
EMBR-27. NEOPLASTIC AND IMMUNE SINGLE CELL TRANSCRIPTOMICS DEFINE SUBGROUP-SPECIFIC INTRA-TUMORAL HETEROGENEITY OF CHILDHOOD MEDULLOBLASTOMA Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Pages i11–i12, https://doi.org/10.1093/neuonc/noab090.044
Published: 01 June 2021
Journal Article
MODL-03. ADAPTING PALBOCICLIB FOR MEDULLOBLASTOMA THERAPY BY IMPROVING DRUG DELIVERY AND ADDRESSING RESISTANCE Open Access
Neuro-Oncology, Volume 22, Issue Supplement_3, December 2020, Page iii412, https://doi.org/10.1093/neuonc/noaa222.580
Published: 04 December 2020
Journal Article
MBRS-46. CHARTING NEOPLASTIC AND IMMUNE CELL HETEROGENEITY IN HUMAN AND GEM MODELS OF MEDULLOBLASTOMA USING scRNAseq Open Access
Neuro-Oncology, Volume 22, Issue Supplement_3, December 2020, Page iii406, https://doi.org/10.1093/neuonc/noaa222.555
Published: 04 December 2020
Journal Article
MBRS-08. SONIC HEDGEHOG SIGNALING PRIMES CEREBELLAR GRANULE NEURON PROGENITORS, THE CELL OF ORIGIN FOR MEDULLOBLASTOMA, FOR APOPTOSIS BY INDUCING PRO APOPTOTIC BIM Open Access
Neuro-Oncology, Volume 22, Issue Supplement_3, December 2020, Page iii400, https://doi.org/10.1093/neuonc/noaa222.527
Published: 04 December 2020
Journal Article
EXTH-56. MEDULLOBLASTOMAS RESPOND TO CDK4/6 INHIBITION WITH NANOPARTICLE-DELIVERED PALBOCICLIB WITH ALTERED S-PHASE PROGRESSION Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi94, https://doi.org/10.1093/neuonc/noz175.387
Published: 11 November 2019
Journal Article
PDTM-05. SONIC HEDGEHOG SIGNALING PRIMES CEREBELLAR GRANULE NEURON PROGENITORS AND MEDULLOBLASTOMA CELLS FOR APOPTOSIS BY INDUCING PRO-APOPTOTIC BIM Free
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Pages vi187–vi188, https://doi.org/10.1093/neuonc/noz175.781
Published: 11 November 2019
